SC
GLUE icon

Stempoint Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

Stempoint Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-61,577
Closed -$966K – 96
2025
Q4 		$966K Buy
+61,577
New +$830K 0.17% 70

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Stempoint Capital's GLUE Position: Q1 2026 in Review

Stempoint Capital sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 61,577 shares — an estimated $966K sold.

Stempoint Capital first reported a position in GLUE in Q4 2025 and held it in 1 quarter. The position peaked at $966K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Stempoint Capital reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 61,577 Monte Rosa Therapeutics shares in Q1 2026, an estimated $966K.
  • Stempoint Capital first reported a position in Monte Rosa Therapeutics in Q4 2025 and held it in 1 quarter.
  • Stempoint Capital's Monte Rosa Therapeutics position peaked at $966K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.